ALNY - Alnylam Pharmaceuticals Inc.

ALNY Stock Chart

ALNY Profile

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to advancing the field of ribonucleic acid interference (RNAi) through the discovery, development, and commercialization of innovative therapeutics. Focused on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases, the company's pipeline of investigational RNAi therapeutics represents a cutting-edge approach to treating a wide range of challenging medical conditions.

Currently, Alnylam Pharmaceuticals markets several breakthrough products including ONPATTRO (patisiran), a lipid complex injection for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for acute hepatic porphyria in adults; and OXLUMO (lumasiran) for primary hyperoxaluria type 1. The company also has a robust pipeline that includes potential treatments for conditions such as chronic HBV infection, hypertension, and non-alcoholic steatohepatitis (NASH), among others.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals has established strategic collaborations with leading pharmaceutical companies like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme to advance RNAi therapeutics across various disease areas. Additionally, the company has forged critical partnerships with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc., underscoring its commitment to driving innovation and expanding treatment options through RNA interference technology.

ALNY Revenue Chart

ALNY Earnings